Efficacy and Safety Of Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience

Temsirolimus (TEM) is an mTOR inhibitor EMA approved for the treatment of patients (pts) with relapsed or refractory (R/R) mantle cell lymphoma (MCL). In a phase III trial TEM 175mg weekly for 3 weeks followed by 75mg weekly significantly improved PFS (4.8 months)  and objective response rate (22%) compared with investigator's choice (1.8 months, 2% respectively). TEM has also been tested in combination with rituximab (RTX) in a phase II trial with encouraging efficacy results (ORR 59%, median time to progression 9.7 months) even in rituximab-refractory pts. However, few data have been reported on the use of TEM in everyday clinical practice.